Literature DB >> 14573657

Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form.

Thomas A Luijkx1, Harry van Dijken, Hendrik-Jan Hamstra, Betsy Kuipers, Peter van der Ley, Loek van Alphen, Germie van den Dobbelsteen.   

Abstract

The hexavalent meningococcal vaccine HexaMen, containing six PorAs on two vesicles, was tested in clinical studies. Although fourfold increases in serum bactericidal activity (SBA) titers against all of the PorAs were observed, there were significant differences between PorA-specific SBA titers. SBA titers were mainly directed against one PorA from each vesicle, P1.5-2,10 and P1.5-1,2-2, and were lower against the other PorAs, especially P1.7-2,4 and P1.19,15-1. We investigated whether these differences were due to immunological interference that resulted in competition between the three PorAs on the same vesicle or whether they were caused by a difference in the immunogenicities of the separate PorAs. Therefore, mice were immunized either with HexaMen, with six monovalent outer membrane vesicles (OMVs) representing the same six PorAs simultaneously (HexaMix), or with only one of the monovalent OMVs. The immunoglobulin G and SBA titers after HexaMen immunization in mice resembled the results obtained in clinical studies. Although immunization with HexaMix gave higher titers than immunization with HexaMen for some PorAs, the pattern of high and low titers was the same. Similar differences in immunogenicity between subtypes were seen after monovalent immunization when interference was eliminated as a cause of the differences. Monovalent immunization resulted in higher titers for P1.5-1,2-2 and P1.7,16 than immunization with HexaMen. However, no significant differences were found for the weakly immunogenic PorAs, P1.7-2,4 and P1.19,15-1. Since immunization with the six PorAs in the trivalent presentation form (HexaMen) and in the mixture of monovalent vesicles (HexaMix) resulted in the same pattern of high and low titers, we concluded that the differences between the PorA-specific responses are due to differences in the immunogenicities of the various PorAs and not due to interference that results in competition between different PorAs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14573657      PMCID: PMC219571          DOI: 10.1128/IAI.71.11.6367-6371.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000.

Authors:  K Cartwright; N Noah; H Peltola
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

2.  Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  A J Lesse; A A Campagnari; W E Bittner; M A Apicella
Journal:  J Immunol Methods       Date:  1990-01-24       Impact factor: 2.303

3.  Topology of outer membrane porins in pathogenic Neisseria spp.

Authors:  P van der Ley; J E Heckels; M Virji; P Hoogerhout; J T Poolman
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

4.  Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP.

Authors:  Bénédicte Manoury; Daniela Mazzeo; Lars Fugger; Nick Viner; Mary Ponsford; Heather Streeter; Graziella Mazza; David C Wraith; Colin Watts
Journal:  Nat Immunol       Date:  2002-01-14       Impact factor: 25.606

5.  Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology.

Authors:  B T McGuinness; P R Lambden; J E Heckels
Journal:  Mol Microbiol       Date:  1993-02       Impact factor: 3.501

6.  Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins.

Authors:  J Tommassen; P Vermeij; M Struyvé; R Benz; J T Poolman
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

7.  Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

Authors:  J Finne; M Leinonen; P H Mäkelä
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

8.  A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels.

Authors:  C M Tsai; C E Frasch
Journal:  Anal Biochem       Date:  1982-01-01       Impact factor: 3.365

9.  IgG antibody subclass responses determined by immunoblot in infants' sera following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine.

Authors:  S Martin; F Sadler; R Borrow; M Dawson; A Fox; K Cartwright
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

10.  Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.

Authors:  J H Fredriksen; E Rosenqvist; E Wedege; K Bryn; G Bjune; L O Frøholm; A K Lindbak; B Møgster; E Namork; U Rye
Journal:  NIPH Ann       Date:  1991-12
View more
  8 in total

1.  Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model.

Authors:  Thomas A Luijkx; Jacqueline A M van Gaans-van den Brink; Harry H van Dijken; Germie P J M van den Dobbelsteen; Cécile A C M van Els
Journal:  Clin Vaccine Immunol       Date:  2008-09-03

2.  Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin.

Authors:  Oliver Koeberling; Anja Seubert; Dan M Granoff
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

3.  Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.

Authors:  Jesús Arenas; Harry van Dijken; Betsy Kuipers; Hendrik Jan Hamstra; Jan Tommassen; Peter van der Ley
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

4.  Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.

Authors:  Bas van de Waterbeemd; Gijsbert Zomer; Patricia Kaaijk; Nicole Ruiterkamp; René H Wijffels; Germie P J M van den Dobbelsteen; Leo A van der Pol
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

5.  Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis.

Authors:  Floris Fransen; Rachel M Stenger; Martien C M Poelen; Harry H van Dijken; Betsy Kuipers; Claire J P Boog; Jos P M van Putten; Cécile A C M van Els; Peter van der Ley
Journal:  PLoS One       Date:  2010-12-23       Impact factor: 3.240

6.  A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.

Authors:  L Marsay; C Dold; C A Green; C S Rollier; G Norheim; M Sadarangani; M Shanyinde; C Brehony; A J Thompson; H Sanders; H Chan; K Haworth; J P Derrick; I M Feavers; M C Maiden; A J Pollard
Journal:  J Infect       Date:  2015-05-15       Impact factor: 6.072

7.  Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.

Authors:  Abel E Vasquez; Ricardo A Manzo; Daniel A Soto; Magaly J Barrientos; Aurora E Maldonado; Macarena Mosqueira; Anastasia Avila; Jorge Touma; Elsa Bruce; Paul R Harris; Alejandro Venegas
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Structure-based design of chimeric antigens for multivalent protein vaccines.

Authors:  S Hollingshead; I Jongerius; R M Exley; S Johnson; S M Lea; C M Tang
Journal:  Nat Commun       Date:  2018-03-13       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.